Page 146 - CW E-Magazine (3-6-2025)

Pharmaceuticals

AIMING HIGH

Lincoln Pharmaceuticals targets Rs. 1,000-crore

revenues in three years

Lincoln Pharmaceuticals, an are derma, cardiac and diabetic. Also
Ahmedabad-based pharmaceutical entity in the domestic market, we are focus-
engaged in the manufacturing of formu- ing more on the ENT segment also
lations, has targeted to achieve because of the Tinnex brand, which we
Rs. 1,000-crore in revenues by the next have and it has been drastically being
three years, a growth of almost 55 accepted throughout the country by
percent. Cardiac, diabetic, derma and the ENTs,” Mr. Patel said. The company
ENT segments are expected to drive the has targeted to grow by 50 percent in
future growth for the company. these four categories in the coming
years.
“We will grow by 15-18 percent grew by 5 percent year-on-year to
yearly. So, we are looking at roughly Rs. 647-crore with states like Uttar “We are looking to invest more into
around Rs. 1,000-crores (in revenues) Pradesh, Assam and Odisha making the the newer molecules and market the
within the next three years,” Mr. Munjal maximum contribution to the revenues product ourselves into various regions
Patel, whole-time director of the from the domestic market. in India as well as in export markets...
company said during an earnings call Looking at the last 6-7 years, we have
hosted by the company after their The company which has been ope- entered various potential markets which
fourth quarter results for fi nancial year rating as a debt-free entity since the were not explored before,” the offi cial
2024-25. last fi ve years also has a presence in said, adding that the company has started
13-15 states. “The top three segments, exporting to Canada and has plans
During FY 25, the company revenues which as a company we are looking at to export to Australia and Germany.

TEMPORARY RELIEF
MSME pharma body seeks waiver of risk-based

inspections

Laghu Udyog Bharati (LUB), an concerns over the quality of Indian “no risk-based inspection should be
association of small businesses which medicines. undertaken, except on critical issues, till
is an affi liate of the Rashtriya Sway- December 2026, and thereafter in case
amsevak Sangh (RSS), has urged the LUB has also sought extension of of further extension,” the letter stated.
government to waive off risk-based the deadline for implementation of
inspections this year for fi rms that are Schedule M for companies which have LUB said it has observed that ins-
upgrading their infrastructure. a turnover of less than Rs. 50-crore. pections of many medium, small and
There are 3,000-4,000 such drug manu- micro enterprises (MSMEs) “were done
In a letter to Union Health Minister facturing units in the country. in a manner which appeared like a raid
JP Naada, LUB has expressed concern and publications showed and treated
over these inspections and sought a “Manufacturers below Rs. 50-crore them as culprits and unlawful promo-
waiver while these companies are up- turnover need your special attention and ters, rather than stakeholders in ‘Make
grading their facilities to comply with handholding for allowing them another in India’ and ‘Ease of Doing Business
the Schedule M requirements, which one-year extension of the deadline for Era’,” the letter said. LUB said that
outlines good manufacturing practices. implementation i.e.; up to 31.12.2026,” some of the units which have been ins-
The inspections were intensifi ed after LUB said in its letter dated May 10. pected are 15-30 years old and have
the World Health Organisation (WHO) On risk-based inspections, it said that played an important role in supplying
and several other countries raised while implementing the Schedule-M, medicines during the COVID pandemic.

146 Chemical Weekly June 3, 2025

Contents Index to Advertisers Index to Products Advertised